Page 103 - TD-4-3

Tumor Discovery Complete response to enfortumab vedotin in mBC

Formal analysis: Osman Köstek 2021;22(6):872-882.
Investigation: Ali Kaan Güren, Murat Sari doi: 10.1016/S1470-2045(21)00094-2
Methodology: Murat Sari, Osman Köstek
Writing – original draft: Ali Kaan Güren 7. Rosenberg JE, Powles T, Sonpavde GP, et al. EV-301 long-
Writing – review & editing: Murat Sari, Osman Köstek term outcomes: 24-month findings from the phase III trial
of enfortumab vedotin versus chemotherapy in patients
Ethics approval and consent to participate with previously treated advanced urothelial carcinoma. Ann
Oncol. 2023;34(11):1047-1054.
The patient gave written informed consent prior to doi: 10.1016/j.annonc.2023.08.016
participation.
8. Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as
Consent for publication first-line treatment in cisplatin-ineligible patients with locally
advanced and metastatic urothelial carcinoma: A single-arm,
The patient provided written informed consent for the multicentre, phase 2 trial. Lancet. 2017;389(10064):67-76.
publication of anonymized data collected during the study.
For person data included in this manuscript (such as doi: 10.1016/S0140-6736(16)32455-2
quotes, images, or case details), consent for publication has 9. Vuky J, Balar AV, Castellano D, et al. Long-term outcomes
been obtained. Identifiable information has been removed in KEYNOTE-052: Phase II study investigating first-line
or anonymized to protect the privacy of participants. pembrolizumab in cisplatin-ineligible patients with locally
advanced or metastatic urothelial cancer. J Clin Oncol.
Availability of data 2020;38(23):2658-2666.
Data will be made available upon reasonable request from doi: 10.1200/JCO.19.01213
the corresponding author. 10. Fradet Y, Bellmunt J, Vaughn DJ, et al. Randomized phase
III KEYNOTE-045 trial of pembrolizumab versus paclitaxel,
References docetaxel, or vinflunine in recurrent advanced urothelial
1. Gore JL, Wright P, Shih V, et al. Development and optimization cancer: Results of >2 years of follow-up. Ann Oncol.
of a bladder cancer algorithm using SEER-Medicare claims 2019;30(6):970-976.
data. JCO Clin Cancer Inform. 2024;8:e2400073. doi: 10.1093/annonc/mdz127
doi: 10.1200/CCI.24.00073 11. Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in
2. Reddy AC, Gu JZ, Koo BH, Fruh V, Sax AJ. Urothelial metastatic urothelial carcinoma after platinum therapy
carcinoma: Epidemiology and imaging-based review. R I (CheckMate 275): A multicentre, single-arm, phase 2 trial.
Med J (2013). 2024;107(5):26-32. Lancet Oncol. 2017;18(3):312-322.
3. Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder cancer: doi: 10.1016/S1470-2045(17)30065-7
A review. JAMA. 2020;324(19):1980-1991. 12. Grivas P, Park SH, Voog E, et al. Avelumab first-line
doi: 10.1001/jama.2020.17598 maintenance therapy for advanced urothelial carcinoma:
Comprehensive clinical subgroup analyses from the JAVELIN
4. Dobruch J, Oszczudłowski M. Bladder cancer: Current Bladder 100 phase 3 trial. Eur Urol. 2023;84(1):95-108.
challenges and future directions. Med (Kaunas).
2021;57(8):749. doi: 10.1016/j.eururo.2023.03.030
doi: 10.3390/medicina57080749 13. Galsky MD, Bajorin DF, Witjes JA, et al. Disease-free
survival analysis for patients with high-risk muscle-invasive
5. Challita-Eid PM, Satpayev D, Yang P, et al. Enfortumab urothelial carcinoma from the randomized CheckMate 274
vedotin antibody-drug conjugate targeting Nectin-4 is trial by PD-L1 combined positive score and tumor cell score.
a highly potent therapeutic agent in multiple preclinical Eur Urol. 2023;83(5):432-440.
cancer models. Cancer Res. 2016;76(10):3003-3013.
doi: 10.1016/j.eururo.2023.01.016
doi: 10.1158/0008-5472.CAN-15-1313
14. Powles T, Valderrama BP, Gupta S, et al. Enfortumab vedotin
6. Yu EY, Petrylak DP, O’Donnell PH, et al. Enfortumab
vedotin after PD-1 or PD-L1 inhibitors in cisplatin- and pembrolizumab in untreated advanced urothelial
ineligible patients with advanced urothelial carcinoma (EV cancer. N Engl J Med. 2024;390(10):875-888.
201): A multicentre, single-arm, phase 2 trial. Lancet Oncol. doi: 10.1056/NEJMoa2312117

Volume 4 Issue 3 (2025) 95 doi: 10.36922/TD025150026